جستجوی استاد راهنمای دانشگاهی

Dr. Vera Deneer is an Associate Professor of Clinical Pharmacology at the Utrecht Institute for Pharmaceutical Research (UIPS) within the Faculty of Science at Utrecht University, specializing in the Division of Pharmacoepidemiology and Clinical Pharmacology since 2019. She also serves as a hospital pharmacist and clinical pharmacologist at the University Medical Center Utrecht (UMC Utrecht) at the Department of Clinical Pharmacy since 2017. Dr. Deneer holds significant leadership positions including Vice-Chair of the Medicines Evaluation Board (MEB-CBG) since 2019 and Chair of the Dutch Pharmacogenetics Working Group (DPWG). Dr. Deneer received her PharmD from Utrecht University in 1991 and her PhD from Groningen University in 2003, with research focused on clinical pharmacology and pharmacokinetics of antiarrhythmic drugs in atrial fibrillation. She completed clinical training in hospital pharmacy in 1994 and clinical pharmacology training in 1998. Prior to her current positions, she served as Head of the Pharmacogenetics, Pharmaceutical and Toxicological Laboratory at St. Antonius Hospital, Nieuwegein/Utrecht from 1998 to 2017. Her research focuses on personalized medicine through the study of biomarkers including genetic variants, patient characteristics, and clinical parameters to optimize drug treatment efficacy and safety. Her work primarily targets cardiovascular disease, lung cancer, and immune-mediated inflammatory diseases. She also investigates clinical reasoning and decision-making by pharmacists to improve medication management in clinical practice. Dr. Deneer serves as principal investigator for multiple research projects funded by The Netherlands Organisation for Health Research and Development. Dr. Deneer's recent publications demonstrate her leadership in pharmacogenetics guidelines development, with numerous Dutch Pharmacogenetics Working Group (DPWG) guidelines published in 2023-2025 covering gene-drug interactions for various medication classes including antidepressants, antipsychotics, anti-epileptics, and cardiovascular medications. Her work spans both clinical implementation research and educational aspects of pharmacy practice. Among her significant appointments, Dr. Deneer serves as Vice-Chair of the Medicines Evaluation Board (MEB-CBG) and Chair of the Dutch Pharmacogenetics Working Group (DPWG). She previously chaired a medical research ethics committee from 2012-2017 and serves on multiple national and hospital committees related to pharmacotherapy and drug safety. Dr. Deneer has been actively involved in mentoring pharmacy students and professionals, with recent publications focusing on clinical decision-making education for pharmacists. Her work bridges the gap between pharmacogenetic research and clinical implementation, with particular emphasis on optimizing drug treatment strategies for individual patients while minimizing adverse drug reactions.

• Pharmacogenetics
• Clinical Pharmacology
• Personalized Medicine
• +۴ مورد دیگر

Hans Bouwmeester is a Full Professor in Toxicology at Wageningen University & Research, specializing in chemical risk assessment, nanomaterial toxicity, and in vitro modeling. His work focuses on integrating artificial intelligence and physiologically based kinetic (PBK) models to predict toxic effects of contaminants like organophosphate pesticides, microplastics, and mycotoxins. He leads projects exploring the health impacts of foodborne contaminants in inflammatory bowel disease and developing animal-free testing methods. Key collaborations include EU initiatives like the ONTOX project and the GUTTEST program, which utilize advanced in vitro models such as gut-on-a-chip systems. Research interests span toxicokinetics, nanoplastics exposure, and the application of Bayesian networks for nanomaterial hazard ranking. His team addresses translational challenges in linking in vitro data to in vivo outcomes, with a focus on bile acid metabolism and cardiotoxicity prediction. Bouwmeester has supervised over 10 PhD candidates, including studies on microplastic hazard assessment, nanomaterial gastrointestinal fate, and AI-driven data extraction for risk assessment. Notable contributions include datasets on nanoplastics' protein corona effects and transcriptomic analyses of intestinal cell responses. His work is published in journals like Ecotoxicology and Environmental Safety , Toxicology , and Environmental Science & Technology , emphasizing open-access research and interdisciplinary approaches to chemical safety.

• Toxicology
• Environmental Toxicology
• Nanomaterial Toxicity
• +۳ مورد دیگر

Professor Sander Nieuwenhuis (Leiden University) specializes in Cognitive Neuroscience of Decision Making through behavioral, EEG, and pharmacological approaches. His work bridges prefrontal cortex function and noradrenergic system mechanisms in human cognition. Studied cognitive psychology (Groningen) and earned PhD (Amsterdam, 2001) International experience: Cambridge University (visiting research), Princeton University (postdoc) Research focuses on noradrenaline's role in attention, decision-making, and cognitive control via: Locus coeruleus-norepinephrine system dynamics Phasic vs. tonic alertness effects Cognitive task performance under neuromodulator deficiency Neuroprotective pathways in Alzheimer's models Recent publications analyze DBH deficiency (Jepma et al., 2011) and attentional blink mechanisms (Nieuwenhuis et al., 2005). His Temporal Attention Lab integrates fMRI, genetics, and computational modeling . Teaching leadership includes: Chair of Research Master Program Committee Coordinator of Scientific Writing courses

• Cognitive Neuroscience
• Decision Making
• Noradrenergic System
• +۳ مورد دیگر

Prof. Robbert Jan Kok is a Professor of Drug Delivery Technology at Utrecht University's Utrecht Institute for Pharmaceutical Sciences (UIPS) and Programme Director for the Bachelor of Pharmacy. He obtained his Pharmacy degree (1993) and PhD in renal drug targeting (1998) from the University of Groningen, followed by postdoctoral research on endothelial-targeted drug delivery. His work spans curriculum development for pharmacy programs and interdisciplinary research in drug innovation. Research Focus: Kok specializes in advanced drug delivery systems, including nanomedicines for kinase inhibitors, 3D-printed formulations, and stimuli-responsive carriers. Key areas include: Targeted delivery to tumors, kidneys, and inflamed tissues Polymeric micelles, liposomes, and microspheres for sustained release Biopharmaceutics and pharmacokinetic optimization Publication Trends: His recent work emphasizes nanotechnology-enabled therapies (e.g., curcumin nanodelivery, photodynamic micelles) and device-integrated drug release (3D-printed implants, macroencapsulation). Studies frequently combine material science with preclinical validation in cancer, renal diseases, and inflammatory disorders. Academic Leadership: Kok oversees student advising, laboratory operations, and international collaborations at UIPS. His team explores translational applications of drug delivery platforms, including partnerships for vascularized tissue engineering and combination therapies.

• Biopharmaceutics
• Drug Targeting
• Nanomedicine
• +۳ مورد دیگر

Prof. A.C.G. (Toine) Egberts is a Professor of Clinical Pharmacoepidemiology and Clinical Pharmacy at Utrecht University's Faculty of Medicine. He leads the Department of Pharmacoepidemiology & Clinical Pharmacology and serves as Director of Doctoral Education at the Graduate School of Life Sciences. His career includes roles as Chief Pharmacist at UMC Utrecht and Board Member of Pharmacy Division. He earned a PharmD from the University of Groningen and a PhD from Utrecht University, specializing in clinical epidemiology. Egberts focuses on reducing drug-related harm through research in adverse effects, sustainable pharmacy practices, and optimizing medication use. With over 500 publications, he sits on editorial boards and committees like CCMO and EPHOR. His work bridges drug development and patient outcomes, emphasizing translational research. Research interests include clinical pharmacology, pharmacoepidemiology, drug sustainability ('green pharmacy'), and innovations in prescribing/monitoring. Key projects like the ROAD study address medication waste reduction, published in JAMA Oncology . Awards include the Senior Jan Glerum Award (2016) and Huizinga Penning for clinical pharmacy contributions. Teaching and mentorship are central: guided over 70 PhD students, emphasizing education in hospital pharmacy. Grants and collaborations span clinical trials, adverse event detection, and AI applications in healthcare. Active in Dutch medicines policy through advisory roles and public media engagement.

• Clinical Pharmacy
• Adverse Drug Effects
• Pharmacoepidemiology
• +۳ مورد دیگر

Birgit Koch is a Full Professor in the Department of Pharmacy at Erasmus MC, affiliated with the Erasmus School of Health Professions. Her work is deeply rooted in clinical pharmacology, with a focus on optimizing drug therapy through pharmacokinetic and pharmacodynamic modeling. Her research interests span pharmacokinetics , pharmacodynamics , therapeutic drug monitoring , and antibiotic dosing , particularly in vulnerable populations such as critically ill and pediatric patients. She has made significant contributions to the understanding of vancomycin and beta-lactam antibiotic pharmacology. The recent articles highlight a consistent trend in clinical pharmacology research, emphasizing population pharmacokinetic modeling , individualized dosing , and evidence-based drug monitoring . Her work bridges laboratory data with real-world clinical outcomes, especially in intensive care and oncology settings. While no specific scientific awards are listed in the provided text, her extensive publication record and leadership in high-impact studies suggest recognition within the field. She has supervised multiple research outputs, indicating an active role in mentoring junior researchers and contributing to academic training. Although specific grants are not mentioned, her involvement in studies like the DOLPHIN trial implies participation in funded research projects. Birgit Koch is part of a robust research network at Erasmus MC, collaborating with experts in oncology, infectious diseases, and clinical pharmacy. Her work is integrated into larger clinical research initiatives, particularly those involving drug optimization and patient-centered pharmacotherapy.

• Clinical Pharmacology
• Pharmacokinetics
• Pharmacodynamics
• +۷ مورد دیگر

Kajie Liang is a Pharmacy Researcher at Erasmus MC, focusing on pharmacological and clinical research. Her work primarily involves therapeutic drug monitoring, clinical pharmacokinetics, and the study of antipsychotic medications in pediatric and adult populations. Dr. Liang's research spans several key areas in pharmacology and toxicology. She has a strong focus on therapeutic drug monitoring, particularly for antipsychotic drugs such as risperidone and aripiprazole. Her work also examines the pharmacokinetics of these drugs in children and adolescents, as well as the metabolic effects including weight gain and alterations in appetite-regulating hormones. Additionally, she has contributed to research on frailty in COVID-19 patients and barriers in multi-center drug trials. Her recent publications (2023-2025) demonstrate a consistent focus on clinical pharmacology, with an emphasis on antipsychotic medications and their effects. She has conducted studies on weight gain and hormonal changes in pediatric patients, case reports on drug intoxication, and reviews on dosing regimens. Her work also extends to geriatric pharmacology, investigating the relationship between frailty and mortality in hospitalized patients.

• Therapeutic Drug Monitoring
• Aripiprazole
• Toxic Injury
• +۵ مورد دیگر

Dr. Antoon Willemsen is a Lecturer in Biomedical Engineering at the University of Groningen’s Faculty of Medical Sciences, associated with the Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE) group. He holds an academic appointment at the UMCG (University Medical Center Groningen) and serves as Chair of the Board of Examiners for Biomedical Engineering. His research focuses on nuclear medicine, molecular imaging, and PET technology, with expertise in radiology, blood-brain barrier analysis, and pharmacokinetic modeling. Key contributions include studies on radiotracer development, P-glycoprotein function assessment, and PET/CT imaging advancements for oncology and neurology applications. Research interests span the UN Sustainable Development Goals, particularly in advancing healthcare technologies. Notable awards include the 2019 Publication Price for established researchers and recognition for top 2018 publications in the Journal of the American Society of Nephrology. His work integrates interdisciplinary approaches, collaborating internationally on topics like amyloid burden quantification and imaging methodology innovations. Recent articles highlight advancements in PET imaging techniques, including image-derived input functions for cerebral studies and comparisons of PET/CT scanner performance. He actively contributes to academic committees like the NVNG and NVKF inspection commissions.

• Nuclear Medicine
• Medical Imaging
• Positron Emission Tomography (PET)
• +۴ مورد دیگر

Prof. Iris Sommer is a Professor of Psychiatry at the University Medical Center Groningen (UMCG) and the University of Groningen. She leads the Clinical Cognitive Neuropsychiatry Research Program (CCNP) and contributes to the Biology-Related, Artificial, and Interventional Neuroscience (BRAIN) group. Her expertise spans neuropsychiatry, with a focus on hallucinations, schizophrenia, and gender disparities in mental healthcare. She is an internationally recognized researcher, having pioneered studies on female brain research, estrogen’s role in psychosis, and innovative treatments like the Stemmenpoli (Voices Clinic). Roles: Editor at Schizophrenia Bulletin, Psychological Medicine, and Lancet Psychiatry. Committee Roles: Chair of ZonMw Offroad Grants Committee, Speaker of the Speakers Academy. Research Interests: Dr. Sommer’s work addresses the origins of psychiatric disorders, particularly schizophrenia and hallucinations. Her key contributions include uncovering estrogen’s protective role in psychotic disorders and advocating for gender-sensitive psychiatric treatments. Recent projects explore gut-brain interactions, probiotics in mental health, and computational linguistics in psychosis diagnosis. Notable Findings: Female brain underrepresentation in clinical studies leads to less effective treatments for women; antipsychotics may suppress beneficial estrogens. Publications & Impact: Over 438 peer-reviewed articles, including high-impact works on hallucinations, COH-FIT pandemic mental health studies, and PET/SPECT imaging in schizophrenia. Her research emphasizes translational medicine and societal impact through public engagement. Awards: Distinguished Lorentz Fellowship (2022/23), Huibregtsenprijs (2022), NWO Science Communication Award (2024), and recognition for science communication initiatives like 'Marvelous Mind.' Labs/Teams: Leads the CCNP, collaborates globally via networks like the HAMLETT and OPHELIA consortia. Active in interdisciplinary projects linking neuroscience, AI, and clinical practice.

• Neuropsychiatry
• Psychiatry
• Schizophrenia
• +۵ مورد دیگر

Prof. Stefan Berger is a Professor of Internal Medicine and Transplantation Nephrology at the University of Groningen's Faculty of Medical Sciences. He holds leadership roles including Chair of the Department of Internal Medicine and Board Member of the UMCG Comprehensive Transplant Center. His research focuses on kidney and pancreas transplantation, complement immunology, clinical trials, and immunosuppression strategies. Key areas include transplantation outcomes in elderly patients and mechanisms of graft rejection. He leads studies on health-related quality of life in transplant recipients and the impact of lifestyle interventions post-transplantation. Research interests span translational and clinical studies in transplantation immunology, with emphasis on biomarkers (e.g., complement activation, fibrosis markers) and optimizing immunosuppressive protocols. His work also addresses long-term outcomes in kidney transplant recipients, including graft survival, metabolic complications, and infection risks. Recent articles highlight contributions to understanding complement activation in sepsis, cellular mechanisms of antibody-mediated rejection, and the efficacy of exercise/diet interventions on transplant recipient outcomes. Collaborations involve multidisciplinary teams across nephrology, immunology, and clinical epidemiology. Prof. Berger is actively involved in national and international transplant networks, contributing to policy through roles like Chair of the UMCG Transplant Center and leadership in the Dutch Transplant Foundation. His translational research bridges laboratory findings to clinical practice, aiming to improve transplant recipient care and outcomes.

• Transplantation Immunology
• Nephrology
• Kidney Transplantation
• +۴ مورد دیگر

Paul Hagedoorn is a Researcher at the Faculty of Science and Engineering , University of Groningen, specializing in Pharmaceutical Technology and Biopharmacy . His work focuses on inhalation technology, pulmonary drug delivery, and medical device development. Expertise in Dry Powder Inhalers and Smart Inhalers Active in Cystic Fibrosis , Parkinson's Disease , and Asthma Treatment Published extensively on Pharmacokinetics and Digital Health applications Recent research includes clinical trials on inhaled Tobramycin for cystic fibrosis and Levodopa formulations for Parkinson's disease. He also explores digital monitoring tools for asthma management. His collaborations span respiratory medicine, neurology, and pharmaceutical engineering, with key contributions to Dry Powder Formulation and Patient-Centered Inhalation Technologies . Contact: p.hagedoorn@rug.nl

• Dry Powder Inhalers
• Pulmonary Drug Delivery
• Cystic Fibrosis
• +۶ مورد دیگر

Dr. Michal Heger is a Researcher at Utrecht University's Faculty of Science, specifically within the Membrane Biochemistry & Biophysics department. He also holds the position of Professor of photonanomedicine at Jiaxing University Medical College in China and serves as Editor-in-chief of the Journal of Clinical and Translational Research. Additionally, he is Chief formulation officer at Nurish.Me in San Diego. Dr. Heger's research primarily focuses on the development of minimally invasive diagnostic and therapeutic modalities for treatment-resistant cancers, with special emphasis on bile duct cancer (extrahepatic cholangiocarcinoma, eCCA). His work follows three pillars: minimally invasive approaches, patient-friendly treatments, and affordable solutions. Photodynamic therapy (PDT) forms the core of his research program, where he investigates nanoscale carrier platforms for photosensitizer delivery, cancer cell responses to PDT, PDT-induced immune responses, and representative cell and animal models for cholangiocarcinoma. His publication record shows significant expertise in photodynamic therapy, with numerous articles spanning from 2012 to 2025. The research trends indicate a strong focus on nanotechnology applications in cancer therapy, particularly in developing targeted delivery systems for photosensitizers and combination therapies. His work bridges basic science with clinical applications, especially in difficult-to-treat cancers where conventional approaches have limited success. Dr. Heger collaborates extensively with various research groups, particularly in the areas of liquid biopsies and molecular profiling for cancer diagnostics and therapy monitoring. His work often involves interdisciplinary approaches combining pharmacology, nanotechnology, and molecular biology to address challenging clinical problems in oncology.

• Photodynamic Therapy
• Nanotechnology
• Cancer Research
• +۵ مورد دیگر

Tine Goedhart is a Researcher in the Department of Pediatrics at Erasmus University Medical Center Rotterdam, specializing in pharmacokinetics, haemophilia, and platelet research. Her work is closely associated with the SYMPHONY consortium, the Thrombocytopathy in the Netherlands (TiN) Study Group, and the OPTI-CLOT study group, focusing on thrombosis and haemostasis. Her research spans Pharmacokinetics , Haemophilia A/B , Blood Clotting Factor 8 , and Platelet Biochemistry . Key areas include optimizing factor concentrate dosing in haemophilia, developing rapid diagnostic tests for platelet disorders, and investigating endothelial cell heterogeneity in vascular diseases. Her work integrates pharmacological modeling with clinical applications to improve treatment strategies for bleeding disorders through: Pharmacokinetic-guided prophylaxis dosing Nanobody-based platelet agonist development Transcriptional profiling of endothelial colony-forming cells Population modeling for pediatric hemophilia B Analysis of her 14 research outputs reveals dominant trends in thrombosis diagnostics , factor replacement therapy optimization , and pediatric pharmacokinetics , with strong emphasis on translational applications for hemophilia management and platelet function disorders. Dr. Goedhart collaborates extensively with international consortia including SYMPHONY, TiN, and OPTI-CLOT, contributing to multi-center studies on haemophilia management and platelet function. While specific grant details are not provided, her research is embedded within these large-scale collaborative projects focused on advancing bleeding disorder treatments. She actively participates in the SYMPHONY consortium and TiN study group, which drive innovation in thrombotic/bleeding disorder research through integrated pharmacokinetic and functional analyses across European institutions.

• Pharmacokinetics
• Haemophilia
• Platelet Research
• +۳ مورد دیگر

Alan Abdulla is a Researcher at the Department of Pharmacy within Erasmus MC, part of Erasmus University Rotterdam. His research focuses on pharmacokinetics, antibiotic efficacy, and therapeutic drug monitoring in critical care settings. He has contributed to studies examining antibiotic target attainment in critically ill patients, including those with obesity and those affected by COVID-19. Key research areas include beta-lactam antibiotics, ciprofloxacin, and ceftriaxone, with emphasis on population pharmacokinetic modeling and dose individualization. His work addresses challenges in achieving optimal antibiotic exposure in complex patient populations to improve clinical outcomes. Collaborations involve multidisciplinary teams investigating pharmacometric approaches to antimicrobial stewardship and infectious disease management. Recent studies highlight the importance of pharmacokinetic/pharmacodynamic (PK/PD) parameters in predicting treatment success and mortality associations.

• Pharmacokinetics
• Antibiotics
• Therapeutic Drug Monitoring
• +۳ مورد دیگر

Liesbeth Ruijgrok serves as a Researcher within the Pharmacy department at Erasmus University Medical Center (Erasmus MC) in Rotterdam, Netherlands. Her academic work bridges pharmaceutical science with clinical applications, focusing on optimizing drug therapies for complex medical conditions through rigorous translational research. Her primary research spans Pharmacology, Toxicology, and Pharmaceutical Sciences with specialized expertise in Adrenal Insufficiency management, Preeclampsia pathophysiology, Drug-Drug Interactions, and advanced Drug Delivery Systems. She pioneers innovative approaches including pharmaceutical 3D printing for personalized hydrocortisone formulations, functional respiratory imaging for aerosol deposition analysis in pediatric asthma, and mechanistic studies of statins in hypertensive pregnancy disorders. Her work consistently addresses critical therapeutic challenges in pharmacokinetics and pharmacodynamics. Analysis of her 2024 publications reveals a strong trend toward solving real-world pharmacotherapy problems through technological innovation and mechanistic understanding. Key themes include cost-effective manufacturing of personalized medicines, precision drug delivery for respiratory diseases, and repurposing existing drugs for novel indications like preeclampsia. Her collaborative studies frequently integrate clinical data with pharmaceutical technology to enhance therapeutic outcomes. No scientific awards were documented in the available profile information. No details regarding student mentorship, research grant funding, or laboratory infrastructure were provided in the source materials. Her research appears to be conducted through multidisciplinary collaborations within Erasmus MC's clinical departments rather than a dedicated independent laboratory.

• Pharmacology
• Toxicology
• Pharmaceutical Sciences
• +۵ مورد دیگر